logo

For the Inventor, By the Inventor

Schlieren, Switzerland

Roche Glycart Ag

USPTO Granted Patents = 73

% Expired Patents = 27.4



Forward Citations = 1,024

Loading Chart...
Loading Chart...

108 inventors (with patents filed for the assignee):

goldMedal Ekkehard Moessner (39 out of 100 patents)

silverMedal Pablo Umana (39 out of 88 patents)

bronzeMedal Christian Klein (34 out of 178 patents)

4.  Ralf Hosse (25 out of 47 patents)

5.  Pablo Umaña (22 out of 47 patents)

6.  Peter Bruenker (18 out of 36 patents)

7.  Thomas U Hofer (17 out of 33 patents)

8.  Anne Freimoser-Grundschober (11 out of 24 patents)

9.  Valeria G Nicolini (11 out of 17 patents)

10.  Ekkehard Mössner (10 out of 15 patents)

11.  Oliver Ast (9 out of 19 patents)

12.  Marina Bacac (9 out of 26 patents)

13.  Guy Georges (8 out of 74 patents)

14.  Joël Jean-Mairet (8 out of 16 patents)

15.  James E Bailey (8 out of 18 patents)


Core Competencies:
Bispecific Antibodies
Immunoconjugates
Glycosylation Engineering
Interleukin-2
Anti-FAP Antibodies
Antigen Binding Molecules
ADCC
Fusion Proteins
Humanized Antibodies
Predictive Biomarkers
Fc Variants
Cancer Treatment

73 patents:

1. 12723084 - 4-1BBL TRIMER-CONTAINING ANTIGEN BINDING MOLECULES (2026-09-01),
2. 12723083 - ANTI-CD3/ANTI-CD28 BISPECIFIC ANTIGEN BINDING MOLECULES (2026-09-01),
3. 12715923 - ANTIBODIES BINDING TO GPRC5D (2026-08-25),
4. 12637522 - MONOCLONAL ANTIBODIES AGAINST BCMA (2026-05-26),
5. 12629419 - PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS (2026-05-19),
6. 12286486 - Anti-FAP antibodies and methods of use (2025-04-29),
7. 11639397 - Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use (2023-05-02),
8. 11459404 - Bispecific T cell activating antigen binding molecules (2022-10-04),
9. 11365232 - Interleukin-2 fusion proteins and uses thereof (2022-06-21),
10. 11332545 - Anti-FAP antibodies and methods of use (2022-05-17),
11. 11214622 - Antibodies specific for DR5 and methods of use (2022-01-04),
12. 11130822 - Immunoconjugates (2021-09-28),
13. 11111312 - Mutant interleukin-2 polypeptides (2021-09-07),
14. 10975151 - ASPGR antibodies and uses thereof (2021-04-13),
15. 10781258 - Bispecific T cell activating antigen binding molecules (2020-09-22),
Company Overview
Roche Glycart AG, based in Schlieren, Switzerland, specializes in advanced antibody engineering, focusing on the development of innovative therapeutic solutions. The company is recognized for its expertise in bispecific antibodies and immunoconjugates, leveraging glycosylation engineering to enhance therapeutic efficacy. Key areas of research include interleukin-2, anti-FAP antibodies, and antigen binding molecules, as well as the exploration of antibody-dependent cellular cytotoxicity (ADCC) and fusion proteins, contributing significantly to the field of biopharmaceuticals.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Roche Glycart Ag USPTO Patent Assignee Logo
73 Patents

#1 in Schlieren

#213 in Switzerland

#10,273 in the World

Schlieren, CH
Schlieren, Switzerland

Roche Glycart Ag

Forward Citations = 1,024

108 inventors:

goldMedal Ekkehard Moessner (39 out of 100 patents)

silverMedal Pablo Umana (39 out of 88 patents)

bronzeMedal Christian Klein (34 out of 178 patents)

4.  Ralf Hosse (25 out of 47 patents)

5.  Pablo Umaña (22 out of 47 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Roche Glycart Ag. Retrieved from https://idiyas.com/company/roche-glycart-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…